About Us
Kangchao Bio-pharmaceutical
Build an efficient R&D and production service platform for health and pharmaceutical products

Tianjin Kangchao Bio-pharmaceutical Co.,Ltd. founded in 2007. Adhering to the development concept of innovation, breakthrough, integration and internationalization, the company has become bigger and stronger around the biomedical and health industry, and has formed a green development system centered on chemical drugs, biological drugs, medical beauty products and medical products, covering the whole field of scientific research, production, marketing and investment.

Based on the research, development and production of high-tech medical technology and products, the company aims at the world's advanced health industry technology and fully realizes the close integration of production, education and research. It maintains a high degree of scientific research cooperation with well-known scientific research institutes at home and abroad, such as Nankai University, Tsinghua University, Sun Yat-sen University, Swiss Federal Institute of Technology, etc., and realizes the transformation of the latest scientific research achievements. There are more than 40 proprietary technologies and nearly 100 innovative products.

The company's founders and main management personnel have rich experience in scientific research, and the R&D team is strong, with more than 80% directly engaged in R&D and production, more than 40% of those with doctoral and master's degrees or above, and 5 people who have returned from overseas study, creating a dynamic and innovative team.

The company will continue to inherit the corporate culture of "pursuit of excellence, rigorous and efficient, focus on pragmatism, pioneering and innovative", and is committed to developing biomedical products with international advanced level. With the development of the basic health industry as the general direction, we will innovate first-class products, provide first-class services, cultivate first-class talents, and achieve first-class enterprises, so as to realize the healthy development of the company and promote the healthy progress of society.

  • 2007
    Establish in
  • 100+
    Innovative product
  • 40+
    Proprietary technology
  • 5
    Overseas returnees
Development history
Our Development
In 2007

In 2007, the company was established by several experienced doctors graduated from Nankai University.

In 2008

In 2008, the company's R&D center was established, and the company transformed into a high-tech enterprise driven by R&D and supported by talents and technology.

In 2009

In 2009, the company won the first prize of "Tianjin Innovation and Entrepreneurship Competition" and the third prize of "China Innovation and Entrepreneurship Competition" in the same year.

In 2012

In 2012, the company was recognized as "Tianjin Science and Technology Small and Medium-sized Enterprise", and the company's product high-performance liquid chromatography acetonitrile was Specialized in the New Small and Medium-Size Enterprises in Tianjin High-tech Suburb.

In 2014

In 2014, the company was successfully listed on the Tianjin Equity Exchange, stock code: 912002. 

In 2015

In 2015, the company's core product choline Alfoscerate  (α-GPC) was commercialized. It has become one of the earliest manufacturers of this product in China to master the large-scale production synthesis technology. 

In 2016

In 2016, the company's core product choline Alfoscerate (α-GPC) successfully entered the Korean market, and successfully developed a liquid phase detection method that has been commonly used in the Korean market.

In 2017

In 2017, the company's core product choline Alfoscerate (α-GPC) successfully entered the United States and Japan market, and the product quality ranked in the leading position in China. In the same year, it was recognized as "Tianjin High-tech Enterprise".

In 2018

In 2018, the company's core product choline Alfoscerate (α-GPC) was registered with the Russian Food and Drug Administration, successfully entered the Russian market, and became the largest supplier of this product in the Russian market. In the same year, the company was recognized as a "national high-tech enterprise".

In 2019

In 2019, the company's core product mexidol achieved commercial production. In the same year, the company was recognized as "Tianjin Specialized and Special New Technology Enterprise" and "Tianjin Gazelle Enterprise".

In 2021

In 2021, the company's core product mexidol was registered with the Russian Food and Drug Administration and successfully entered the Russian market. In the same year, the company was recognized as "National Intellectual Property Advantage Enterprise".

In 2023

In 2023, the company, together with the School of Chemistry of Nankai University and the Academy of Sciences of Nankai University, will jointly establish a scientific and technological innovation platform in Tianjin TFI Higher Education Science and Technology Innovation Park. In the same year, the company was approved as a "national expert service base".

In 2024

In 2024, choline Alfoscerate (α-GPC) was approved as a national new food raw material, and the company has developed and produced a series of new resource foods to contribute to human health.

Fulture

We will continue to make unremitting efforts in the future.

In 2007
In 2008
In 2009
In 2012
In 2014
In 2015
In 2016
In 2017
In 2018
In 2019
In 2021
In 2023
In 2024
Fulture
Corporate culture
The company will continue to inherit the corporate culture of "pursuit of excellence, rigorous and efficient, focus on pragmatism, pioneering and innovative", and is committed to developing biomedical products with international advanced level. With the development of the basic health industry as the general direction, we will innovate first-class products, provide first-class services, cultivate first-class talents, and achieve first-class enterprises, so as to realize the healthy development of the company and promote the healthy progress of society.
Honors
  • Certificate
  • Patent
  • Management system